Search

Your search keyword '"Youngstein, T"' showing total 73 results

Search Constraints

Start Over You searched for: Author "Youngstein, T" Remove constraint Author: "Youngstein, T" Publication Year Range Last 10 years Remove constraint Publication Year Range: Last 10 years
73 results on '"Youngstein, T"'

Search Results

1. Long-term (180-day) outcomes in critically ill patients with COVID-19 in the REMAP-CAP randomized clinical trial

2. INSAID Variant Classification and Eurofever Criteria Guide Optimal Treatment Strategy in Patients with TRAPS: Data from the Eurofever Registry

3. Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA)

4. Diagnostic Challenges in Sepsis

5. INSAID Variant Classification and Eurofever Criteria Guide Optimal Treatment Strategy in Patients with TRAPS: Data from the Eurofever Registry

6. INSAID Variant Classification and Eurofever Criteria Guide Optimal Treatment Strategy in Patients with TRAPS: Data from the Eurofever Registry

8. FRI0457 LONG-TERM OUTCOMES AND TREATMENT EFFICACY IN PATIENTS WITH TNF RECEPTOR-ASSOCIATED AUTOINFLAMMATORY SYNDROME (TRAPS) FROM THE EUROFEVER INTERNATIONAL REGISTRY

9. Molecular genetic investigation, clinical features and response to treatment in 21 patients with Schnitzler's syndrome

10. PET Imaging in Takayasu Disease Requiring Arterial Grafts REPLY

11. 18F-FDG uptake by prosthetic arterial grafts in large vessel vasculitis is not specific for active disease: results from a cohort study

12. International multi-centre study of pregnancy outcomes with interleukin-1 inhibitors

15. International experience of pregnancy outcomes in auto-inflammatory syndromes treated with Interleukin-1 inhibitors

17. Bleeding diathesis and prothrombotic tendencies in patients with newly diagnosed systemic light chain Amyloidosis: important clinical implications

18. SAT0553 Anti-Interleukin-1 Therapies and Pregnancy Outcome: an International Cohort

20. Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA)

21. INSAID Variant Classification and Eurofever Criteria Guide Optimal Treatment Strategy in Patients with TRAPS: Data from the Eurofever Registry

22. Proteomic Profiling of the Large-Vessel Vasculitis Spectrum Identifying Shared Signatures of Innate Immune Activation and Stromal Remodeling.

23. A protocol for targeted B-lymphocyte depletion for the treatment of IgG4-related disease.

24. Current understanding and management of cardiovascular involvement in rheumatic immune-mediated inflammatory diseases.

25. Acute cardiovascular complications of immune-mediated systemic inflammatory diseases.

29. Haemophagocytic lymphohistiocytosis in pregnancy.

30. Large-vessel vasculitis.

32. A rare life-threatening presentation of Takayasu arteritis.

33. The utility of a local multidisciplinary working group to oversee the establishment of rapidly evolving standards of care and to support trial recruitment during the COVID-19 pandemic.

34. Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia.

35. Multi-arm Trial of Inflammatory Signal Inhibitors (MATIS) for hospitalised patients with mild or moderate COVID-19 pneumonia: a structured summary of a study protocol for a randomised controlled trial.

36. Gastroenteritis and cardiogenic shock in a healthcare worker: a case report of COVID-19 myocarditis confirmed with serology.

37. The Impact of Integrated Noninvasive Imaging in the Management of Takayasu Arteritis.

38. Diagnostic Challenges in Sepsis.

39. Coronavirus disease 2019: investigational therapies in the prevention and treatment of hyperinflammation.

41. Identifying rheumatic disease patients at high risk and requiring shielding during the COVID-19 pandemic.

42. Biologic therapy in supra-aortic Takayasu arteritis can improve symptoms of cerebral ischaemia without surgical intervention.

44. British kindred with dominant FMF associated with high incidence of AA amyloidosis caused by novel MEFV variant, and a review of the literature.

46. Cardiorenal AL amyloidosis: risk stratification and outcomes based upon cardiac and renal biomarkers.

47. Bioimpedance vector analysis for the detection of extracellular volume overload and sarcopenia in systemic AL amyloidosis.

48. Novel Angiographic Scores for evaluation of Large Vessel Vasculitis.

49. Role of implantable intracardiac defibrillators in patients with cardiac immunoglobulin light chain amyloidosis.

50. Rapid hematologic responses improve outcomes in patients with very advanced (stage IIIb) cardiac immunoglobulin light chain amyloidosis.

Catalog

Books, media, physical & digital resources